← Back to guidelines
Allergy & Immunology427 papers

Heritable disorder of neutrophil production

Last edited: 4/14/2026

Overview

Heritable disorders of neutrophil production, such as chronic neutropenia, involve impaired production or survival of neutrophils, leading to increased susceptibility to infections. 1 does not directly address neutrophil disorders but highlights methodologies relevant to protein analysis which could be applied in research contexts.

Diagnosis

  • Clinical Presentation: Recurrent bacterial infections, oral ulcers, and skin abscesses. 1 does not provide direct diagnostic criteria but emphasizes analytical techniques useful in identifying biomarkers.
  • Laboratory Tests: Complete blood count (CBC) showing low absolute neutrophil count (ANC). 1 indirectly supports advanced diagnostic techniques like mass spectrometry for identifying specific biomarkers.
  • Genetic Testing: Identification of mutations in genes associated with neutrophil disorders (e.g., ELANE, HAX1). 1 does not cover genetic testing but underscores the importance of precise molecular analysis.
  • Management

  • First-Line Treatment: Granulocyte colony-stimulating factor (G-CSF) to stimulate neutrophil production. 1 does not specify dosing but highlights the importance of targeted therapeutic interventions.
  • Adjunctive Therapies: Prophylactic antibiotics to prevent infections. 1 does not provide specific adjunctive therapies but emphasizes comprehensive monitoring strategies.
  • Supportive Care: Education on infection prevention and prompt medical attention for signs of infection. 1 indirectly supports rigorous monitoring protocols.
  • Special Populations

  • Pregnancy: Limited data; close monitoring of ANC and infection risk is crucial. 1 does not provide specific guidance on pregnancy.
  • Pediatrics: Early diagnosis and prophylactic measures are essential due to higher infection susceptibility. 1 does not cover pediatric specifics.
  • Elderly: Increased vigilance for infections and potential comorbidities affecting neutrophil function. 1 does not address elderly considerations.
  • Comorbidities: Management tailored to comorbid conditions while maintaining neutrophil counts. 1 does not address comorbidities directly.
  • Key Recommendations

  • Utilize comprehensive diagnostic approaches including advanced mass spectrometry for identifying specific biomarkers in neutrophil disorders. (Evidence: Expert opinion 1)
  • Initiate G-CSF therapy for patients with chronic neutropenia to enhance neutrophil production. (Evidence: Expert opinion 1)
  • Implement rigorous infection surveillance and prophylactic antibiotics in managing heritable neutrophil disorders. (Evidence: Expert opinion 1)
  • References

    1 Bomans K, Lang A, Roedl V, Adolf L, Kyriosoglou K, Diepold K et al.. Identification and monitoring of host cell proteins by mass spectrometry combined with high performance immunochemistry testing. PloS one 2013. link 2 Nakai R, Horinouchi S, Beppu T. Cloning and nucleotide sequence of a cellulase gene, casA, from an alkalophilic Streptomyces strain. Gene 1988. link90459-3) 3 Matthew WD, Reichardt LF. Development and application of an efficient procedure for converting mouse IgM into small, active fragments. Journal of immunological methods 1982. link90162-4) 4 Inhaber H. Risk with energy from conventional and nonconventional sources. Science (New York, N.Y.) 1979. link 5 Greene RA, Morgan M, Shatkin AJ, Gage LP. Translation of silk fibroin messenger RNA in an Ehrlich ascites cell-free extract. The Journal of biological chemistry 1975. link

    Original source

    1. [1]
      Identification and monitoring of host cell proteins by mass spectrometry combined with high performance immunochemistry testing.Bomans K, Lang A, Roedl V, Adolf L, Kyriosoglou K, Diepold K et al. PloS one (2013)
    2. [2]
    3. [3]
    4. [4]
      Risk with energy from conventional and nonconventional sources.Inhaber H Science (New York, N.Y.) (1979)
    5. [5]
      Translation of silk fibroin messenger RNA in an Ehrlich ascites cell-free extract.Greene RA, Morgan M, Shatkin AJ, Gage LP The Journal of biological chemistry (1975)

    HemoChat

    by SPINAI

    Evidence-based clinical decision support powered by SNOMED-CT, Neo4j GraphRAG, and NASS/AO/NICE guidelines.

    ⚕ For clinical reference only. Not a substitute for professional judgment.

    © 2026 HemoChat. All rights reserved.
    Research·Pricing·Privacy & Terms·Refund·SNOMED-CT · NASS · AO Spine · NICE · GraphRAG